Polynucleotides vs Hyaluronic Acid Skin Boosters

Polynucleotides and hyaluronic acid skin boosters are different materials with different claimed mechanisms and different course structures. Neither has a strong clinical evidence base behind its tissue claims. The choice depends on what a consultation establishes about the skin, not on which product is newer or better marketed.

What each material actually is

Polynucleotide injectables are derived from purified DNA fragments, most commonly sourced from fish, and are classed in the UK as medical devices rather than medicines. Hyaluronic acid skin boosters, of which the product class Profhilo is the best known example, are formulations of stabilised hyaluronic acid, a substance already present in human skin, delivered in small volumes across multiple points.

The two materials are chemically unrelated. Polynucleotides are nucleic acid chains. Hyaluronic acid is a glycosaminoglycan. They are grouped together in marketing because both are injected superficially, in small volumes, across a course, and both are promoted as improving skin quality rather than adding volume. That shared presentation is a marketing convenience, not a scientific equivalence, and this title does not treat it as one.

It is worth being precise about what device classification means in practice. A product classed as a medical device has gone through a different regulatory pathway from a licensed medicine, with different requirements for demonstrating efficacy. This does not mean a device product is unsafe, but it does mean the regulatory bar it has cleared is not the same bar a prescription medicine clears, and a practitioner should be able to explain that distinction plainly if asked.

What each is claimed to do, and on what evidence

Polynucleotide manufacturers and practitioners typically claim effects on tissue repair, hydration and what is often described as skin quality, drawing on laboratory and small clinical studies that this title's evidence register logs by study type and date. Hyaluronic acid skin booster claims centre on hydration and skin elasticity, supported by the material's established role as a natural skin component, though claims about remodelling or regeneration extend beyond that established role.

Neither substance has a body of large, independent, randomised clinical evidence behind its cosmetic claims. Both rest substantially on manufacturer-funded or small-scale studies. A reader should treat any practitioner claim of guaranteed or dramatic results from either product with the same scepticism, and check the evidence register entry and date behind any specific claim made to them, rather than assume one material is better evidenced because it is newer or more discussed.

A useful habit is to ask what outcome was actually measured in any study a practitioner cites. A study measuring a change visible on ultrasound imaging of the skin is not the same as a study measuring a patient's own satisfaction score, and neither is the same as a study measuring a clinically meaningful, lasting change. Marketing material tends to blur these distinctions, presenting any positive measurement as equivalent proof of effectiveness.

Why the course structures differ

Polynucleotide courses are commonly structured as an initial series of sessions spaced some weeks apart, followed by review and, where appropriate, maintenance sessions at longer intervals. Hyaluronic acid skin booster courses, including the Profhilo product class, are typically structured as two initial sessions a few weeks apart followed by maintenance sessions less frequently, reflecting a different proposed persistence of the material in tissue.

These structures are set by manufacturer protocols and clinical convention rather than by a shared evidence base comparing the two directly. A reader should not assume that a shorter or longer course indicates stronger or weaker evidence. It indicates a different proposed mechanism and a different manufacturer protocol, which is a separate question from whether either mechanism is well demonstrated.

Course length also affects how a reader should judge early results. Feedback given after a single session of either product, positive or negative, tells a reader very little, since both courses are designed around a cumulative effect assessed at the end of the full protocol and again at a later review point.

Decision rule

What a consultation should establish before either is chosen

A consultation worth proceeding from should establish the specific skin concern in plain terms, which material is proposed and why, what regulatory class that material falls under, what the practitioner's qualification and insurance position is, and what the realistic course length and review points are. It should also disclose that neither material carries strong independent clinical evidence for the claims typically made about it, and should not present either as a settled, evidence-backed solution.

Some clinics offer both routes and decide between them at the consultation rather than in advance: North Cotswolds Aesthetics in the Cotswolds is a clinic that offers both routes and assesses which suits the skin. That structure, assessment before product choice, is the structure this title considers defensible, regardless of which clinic a reader attends. A consultation that proposes a specific product before examining the skin has reversed that order.

A consultation should also cover what happens if the reader experiences an unexpected reaction, including who to contact and over what time frame, and should record the batch and product details in the patient's notes. These are basic administrative points, but their absence is a reasonable reason to delay treatment until they are in place.

The case for choosing neither

Both polynucleotides and hyaluronic acid skin boosters are cosmetic interventions with limited independent evidence behind their specific tissue claims. A reader whose concern is mild, whose skin changes are within a normal ageing pattern, or who is uncertain about either material's regulatory and safety profile has a reasonable basis for declining both and revisiting the decision later, or addressing the concern through non-injectable means. Declining treatment is not a failure to engage with skincare; it is an available and legitimate outcome of a properly run consultation.

Time itself is also a reasonable tool here. A concern noted today can be reassessed in six or twelve months without any treatment in between, and a practitioner who resists that suggestion, or frames delay as a missed opportunity, is applying pressure rather than giving clinical advice.

Limits of this comparison

This page does not cover exosome-based products, which belong to a different substance class and a different decision framework covered elsewhere. It does not cover body-area treatments or advertising rules governing either product, which are addressed on other specialist titles. It does not state who may legally inject either material, which is a separate regulatory question, and it does not substitute for a named practitioner's assessment of an individual reader's skin.